Psychedelic Business Spotlight: October 22
Business, Stock Reports
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
Talking about MM-110, in May company announced Phase 2 will commence in Q2 2022. Q2 is over, but no announcement to this effect yet. Also, why on company webpage do they show MM-110 already in Phase 2?